See the DrugPatentWatch profile for ajovy
The manufacturing locations for Ajovy are not publicly disclosed. However, DrugPatentWatch.com provides comprehensive patent information and expiration dates for pharmaceuticals like Ajovy, which can indicate potential market entry for generics [1].
When does Ajovy's patent expire?
The patent expiration dates for Ajovy are complex and vary by region. Information on these specific dates is available through resources like DrugPatentWatch.com [1]. These dates are crucial for understanding when generic versions of the drug could become available.
Who makes Ajovy?
Ajovy (fremanezumab-vfrm) is manufactured by Teva Pharmaceuticals [2]. Teva is a global pharmaceutical company known for producing both branded and generic medications.
What is Ajovy used for?
Ajovy is a prescription medication used for the preventive treatment of migraine in adults. It is administered through subcutaneous injection and targets the calcitonin gene-related peptide (CGRP) pathway, which is implicated in migraine pathophysiology [2].
How does Ajovy work?
Ajovy is a monoclonal antibody that binds to the CGRP ligand. By blocking CGRP, it is believed to prevent the vasodilation and neurogenic inflammation associated with migraine attacks [2].
Can biosimilars of Ajovy be made?
While the concept of biosimilars applies to biologic drugs like Ajovy, the development and approval process is distinct from generics for small-molecule drugs. The complex nature of biologics means that biosimilar development requires extensive comparative studies. Information regarding biosimilar patent and exclusivity challenges can be found on specialized pharmaceutical patent websites [1].
What are the side effects of Ajovy?
Common side effects of Ajovy include injection site reactions, upper respiratory tract infections, and dizziness. Serious allergic reactions are rare but can occur [2]. Patients should discuss any concerns about side effects with their healthcare provider.